Tumour immune cells can aid cancer therapies: Study

Analysts for a recent study, designed a pioneering technique to spot differences between immune cells in tumours that could speed the development of cancer treatments.

Researchers at the University of Edinburgh analysed genes from anonymised medical databases of thousands of tumours to identify genes associated with immune cells. The findings of the study are published in the Journal of Cancer Immunology Research.

Scientists said that the approach could be used to help doctors choose the best treatments for individual patients and predict which tumours are likely to respond to a particular therapy.

It could also help to target the use of immunotherapy - a new form of treatment that uses the body's own defences to tackle cancer. This therapy has shown great promise in recent years, but identifying which patients will respond best is a challenge for doctors.

The new approach - based on gene analysis - makes it easier to spot the range of immune cells present in a tumour. These cells could help the body detect and kill cancer when activated by certain drugs, scientists say.

Traditional treatments, such as radiology, do not discriminate between cell types and attack both cancerous and healthy cells, often leading to side-effects.

A source called ImSig - paints the best picture of tumours to date and will allow scientists to study how certain immune cell types affect cancer growth.


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel